BiotechTube

Evobrutinib + Evobrutinib + Evobrutinib + Placebo + Tecfidera

Phase 2Terminated
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Relapsing-remitting Multiple Sclerosis

Conditions

Relapsing-remitting Multiple Sclerosis

Trial Timeline

Mar 7, 2017 → Apr 2, 2024

NCT ID
NCT02975349

About Evobrutinib + Evobrutinib + Evobrutinib + Placebo + Tecfidera

Evobrutinib + Evobrutinib + Evobrutinib + Placebo + Tecfidera is a phase 2 stage product being developed by Merck for Relapsing-remitting Multiple Sclerosis. The current trial status is terminated. This product is registered under clinical trial identifier NCT02975349. Target conditions include Relapsing-remitting Multiple Sclerosis.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (1)

NCT IDPhaseStatus
NCT02975349Phase 2Terminated

Competing Products

20 competing products in Relapsing-remitting Multiple Sclerosis

See all competitors
ProductCompanyStageHype Score
CT-P53 + US-Ocrevus + EU-OcrevusCelltrionPhase 3
77
LY2127399 + PlaceboEli LillyPhase 2
52
BIIB019 (Daclizumab High Yield Process) + PlaceboAbbViePhase 2
52
DaclizumabAbbViePhase 3
77
BIIB019 (Daclizumab High Yield Process) + PlaceboAbbViePhase 2
52
BIIB019 (Daclizumab) + trivalent seasonal influenza vaccineAbbViePhase 2
52
BIIB019 (Daclizumab)AbbViePhase 3
77
BIIB019 (Daclizumab High Yield Process) + Interferon beta-1a Placebo + Interferon beta-1a + Daclizumab High Yield Process PlaceboAbbViePhase 3
77
Rebif (Interferon beta-1a)MerckPre-clinical
23
Interferon beta-1aMerckPre-clinical
23
Rebif® + Avonex®MerckPhase 3
77
Rebif® + Rebif®MerckApproved
85
VigantOL oil plus interferon beta-1a (Rebif) + Placebo plus interferon beta-1a (Rebif) + Interferon beta-1a (Rebif®) aloneMerckPhase 2
52
Placebo + IFN beta-1a + MethylprednisoloneMerckPhase 2
52
Interferon beta-1a (Rebif)MerckApproved
85
Evobrutinib + Avonex® + Avonex® matched Placebo + Evobrutinib matched PlaceboMerckPhase 3
77
Evobrutinib + Avonex® + Avonex® matched Placebo + Evobrutinib matched PlaceboMerckPhase 3
77
Interferon beta 1aMerckPre-clinical
23
Cladribine 10 mg oral tabletMerckApproved
85
Minocycline + PlaceboMerckPhase 2
52

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85